Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SR34006 (idraparinux sodium) Injection, Idraparinux sodium
SR34006 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| SR34006 (idraparinux sodium) Injection | DRUG | - |
| vitamin K antagonist (warfarin or acenocoumarol) tablets | DRUG | - |
| SR34006 | DRUG | - |
| (LMW)heparin | DRUG | - |
| Warfarin VKA | DRUG | - |
| Acenocoumarol VKA | DRUG | - |
Inclusion Criteria: * Patients with confirmed symptomatic Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) who have been treated with acenocoumarol, warfarin or SR34006 for six months * Written informed consent Exclusion Criteria: * Legal age limitations (country specific) * Indication for a...
Top 5 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | REGN7508, REGN9933 |
| Johnson & Johnson | JNJ | 14 | PHASE3 | Milvexian |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Abelacimab, PKN605 |
| Milestone Pharmaceuticals, Inc. | MIST | 1 | PHASE3 | Etripamil |
| Bayer | BAYRY | 1 | PHASE2 | BAY 3670549 |
SR34006 is an investigational small molecule anticoagulant developed by Sanofi. It has been studied in Phase 3 clinical trials for cardiovascular conditions, specifically atrial fibrillation and pulmonary embolism. It is also known as idraparinux sodium and is given as an injection.
SR34006 has been studied for the treatment and prevention of thromboembolic conditions, including atrial fibrillation and pulmonary embolism. Clinical trials evaluated it in patients with atrial fibrillation and in patients with symptomatic pulmonary embolism or deep vein thrombosis. It is investigational and not approved for commercial use.
SR34006 is developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the Phase 3 clinical program evaluating the drug in atrial fibrillation and pulmonary embolism.
SR34006 reached Phase 3 clinical development. Two completed Phase 3 trials are registered, and no trials are currently active. The drug is investigational and has not been approved by the FDA for any indication.
SR34006 was evaluated in Phase 3 trials including NCT00070655, the AMADEUS study comparing it to warfarin or acenocoumarol in atrial fibrillation, NCT00071279 comparing it to placebo after six months of treatment for pulmonary embolism or deep vein thrombosis, and NCT00062803 comparing it to a vitamin K antagonist in pulmonary embolism.
Yes, SR34006 is also known as idraparinux sodium. The full name used in study listings is SR34006 (idraparinux sodium) Injection. Both names refer to the same investigational Sanofi anticoagulant studied in Phase 3 trials for atrial fibrillation and pulmonary embolism.